Phage Australia

Phage Australia

A national network of phage researchers and clinician scientists who aim to professionalise phage therapy as the third major intervention for infectious diseases.
Patients treated
Investigators and Partners
Treatment Sites
Registered phages
Registered strains

Our journey to treating Dhanvi

In 2019, 7-year-old Dhanvi was in a car accident. The bones in her legs became infected with bacteria. Antibiotics didn't help, and she faced amputation

Read about Dhanvi →

Dhanvi cover

How does phage therapy work?

If the right phage can be found in time, phages can be used like antibiotics to cure life-threatening bacterial infections

How does it work? →

3D phage rendering

Our approach to phage therapy

How we’re tackling phage therapy’s decades-long paradox using a personalised clinical trial

Our approach →

WIMR aerial shot

Join our Network

Are you at a hospital in Australia? Are you with a patient advocate group? Do you run a phage lab, even outside of Australia? We’d still love to work with you.

Phage Australia is bigger than Australia! We currently work with Phage Canada and phage teams in the UK to expand the reach of STAMP-regulated phage therapy.


Explore the biobank
Register your Biobank
We are now ready to register all Phage Australia node biobanks!
Registering your phages and bacterial strains speeds up our phage therapy efforts.

Iredell Lab

Lab Name
Iredell Lab
Contact Name
Jan Zheng
Contact Email
Westmead Institute for Medical Research
Registered Strains: 5396
Strain genera: Achromobacter (2), Acinetobacter (103), Aeromonas (4), Chryseobacterium (2), Citrobacter (231), Cupriavidus (1), Cupriviadus (1), Edwardsiella (1), Elizabethkingia (1), Enterobacter (837), Enterococcus (21), Escherichia (2477), Hafnia (7), Klebsiella (1106), Kluyvera (3), Morganella (26), Pantoea (3), Proteus (49), Providencia (4), Pseudomonas (316), Raoultella (1), Salmonella (9), Serratia (117), Shigella (26), Staphylococcus (43), Stenotrophomonas (4)
Registered Phages: 342
Phage host genera: Enterococcus (7), Escherichia (85), Klebsiella (48), Pseudomonas (30), Staphylococcus (47)
View Registered Phages (342)
View Registered Strains (5396)

The Bacteriophage Bank of Korea

Lab Name
The Bacteriophage Bank of Korea
Contact Name
Heejoon Myung
Contact Email
Lysentech, Hankuk Univsersity of Foreign Studies
Registered Strains: 0
Strain genera:
Registered Phages: 1964
Phage host genera: Acinetobacter (118), Campylobacter (102), Cronobacter (86), Enterobacter (199), Enterococcus (19), Escherichia (357), Klebsiella (102), Lactobacilus (7), Pectobacterium (1), Pseudomonas (249), Salmonella (229), Serratia (25), Shigella (107), Staphylococcus (8), salmonella (273), shigella (82)
View Registered Phages (1964)
View Registered Strains (0)

EMG lab

Lab Name
EMG lab
Environmental Microbial Genomics – Institut for Plante- og Miljøvidenskab - Københavns Universitet
Contact Name
Lars H. Hansen
Contact Email
University of Copenhagen
Registered Strains: 1
Strain genera: Salmonella (1)
Registered Phages: 38
Phage host genera: Enterrococcus (1), Escherichia (24), Pseudomonas (6), Salmonella (6), acinetobacter (1)
View Registered Phages (38)
View Registered Strains (1)

Blog Posts

In the News

If you're in the network, add your Phage Australia news here
Publication | June 21, 2023
Publication | June 16, 2023
News | June 03, 2023
Phage Therapy PK/PD Review Paper

Bacteriophages (phages) are viruses with the ability to infect bacteria, and they have recently attracted substantial attention as potential therapeutic alternatives or adjuvants to antibiotic therapy due to the global urgency of antimicrobial resistance. Antibiotics have been the clinical ‘gold standard’ for treating bacterial infections, and their pharmacokinetics/pharmacodynamics (PK/PD) have been extensively investigated over the past decades. Unfortunately, there has been a significant lack of research on the PK/PD of phage therapy, severely hindering its clinical translation. Recognising this as a major hurdle, excellent reviews summarising the available literature on phage PK/PD have been published over recent years. The aim of this present narrative review is to discuss the PK/PD challenges with the clinical translation of phage therapy and address the voids that need to be filled.

Clinical Microbiology and Infection
Phage Therapy Polyclonal Bacteraemia Staphylococcus aureus

Staphylococcus aureus is a leading cause of bacteraemia and endocarditis in which intraclonal genetic variation, but not true polyclonal bacteraemia, is well documented. We describe a case of 36-year-old women with simultaneous and persistent bacteremia from two strains of Staphylococcus aureus that probably would have gone unrecognised because of the identical antibiotic profiles if had we not used bacteriophage susceptibility (“phage typing”) to further characterise the strains. In this patient, the dual bacteraemia was followed months later by another bacteraemia that likely would have been deemed a relapse of the original infection, except that we used similar methods to identify a third and unrelated strain. Our patient eventually responded well to antibiotics, and her bacteriophage therapy probably contributed little to that recovery. However, bacteriophage therapy required that we identify the strain of S. aureus causing her bacteraemia, and that requirement led directly to our identification of dual strains with identical antibiotic susceptibilities. Because of this experience, we alert other clinicians to the possibility of polyclonal infections with S. aureus. When bacteraemia is suspected, clinicians often pick a single colony or a few colonies from the original culture because prompt identification of the organism is critical and this practice provides a faster turnaround time. We caution that it might not identify different strains with different antibiotic sensitivities when polyclonal infections are present.

Annals of Internal Medicine
L-forms Antibiotic resistance Phages Escherichia coli

Bacterial L-forms require specialized culture techniques and are neither widely reported nor well understood in human infections. To date, most of the studies have been conducted on Gram-positive and stable L-form bacteria, which usually require mutagenesis or long-term passages for their generation. Here, using an adapted osmoprotective growth media, we provide evidence that pathogenic E. coli can efficiently switch to L-forms and back to a cell-walled state, proliferating aerobically in supratherapeutic concentrations of antibiotics targeting cell walls with few or no changes in their DNA sequences. Our work demonstrates that L-form switching is an effective adaptive strategy in stressful environments and can be expected to limit the efficacy of β-lactam and phages for many important infections.

Microbiology Spectrum
Phage biology Phage Therapy Phage-bacterium dynamics Antimicrobials

Bacteriophages (phages) are selective viral predators of bacteria. Abundant and ubiquitous in nature, phages can be used to treat bacterial infections (phage therapy), including refractory infections and those resistant to antibiotics. However, despite an abundance of anecdotal evidence of efficacy, significant hurdles remain before routine implementation of phage therapy into medical practice, including a dearth of robust clinical trial data. Phage–bacterium interactions are complex and diverse, characterized by co-evolution trajectories that are significantly influenced by the environments in which they occur (mammalian body sites, water, soil, etc.). An understanding of the molecular mechanisms underpinning these dynamics is essential for successful clinical translation. This review aims to cover key aspects of bacterium–phage interactions that affect bacterial killing by describing the most relevant published literature and detailing the current knowledge gaps most likely to influence therapeutic success.

EMBO Molecular Medicine
Online Course Phage therapy ESCMID ESGNTA

The first phage therapy course jointly organised by ESCMID (European Society of Clinical Microbiology and Infectious Diseases) and ESGNTA (ESCMID Study Group for Non-traditional Antibacterial Therapy) and includes four sessions with cutting-edge scientific talks in the field of personalised phage therapy : (1) therapeutic monitoring (2) immune response to bacteriophages (3) formulation and administration of bacteriophages for therapy, and (4) current state and prospects of oral phage therapy, followed by live Q&A sessions and panel discussion.

ESCMID Online Course 2022
News | August 31, 2022
Phage Therapy

Academics plan to roll out therapy widely in Australia: Researchers at the University of Sydney, Western Sydney Local Health District and the Westmead Institute for Medical Research are developing a therapeutic solution to antimicrobial resistance that predates the discovery and wide usage of antibiotics… Link to Paper

News | August 17, 2022
Phage Therapy

An expert team, led by Director of the Centre of Infectious Diseases and Microbiology at the Westmead Institute for Medical Research (WIMR) Professor Jon Iredell, is developing a key alternative to antibiotics and central to the treatment are phages…

Twitter | July 15, 2022
Phage Therapy
Twitter | July 05, 2022
FundingPhage Therapy
Read all news

Who we are

We are a network of clinicians, researchers, microbiologists, and engineers passionate about tackling the next existential threat to humanity

© 2024 Phage Australia